Lates News

According to a news flash from Meijing AI, Southwest Securities issued a research report on May 6, giving a holding rating to Sino Biopharmaceutical (600201.SH). The reasons for the rating mainly include: 1) the industry is in a low point, with performance under pressure, and adjusting strategies to actively compete; 2) the funding pressure of companies in the breeding industry is reduced or increased, which may improve the willingness to purchase animal protection products; 3) adhering to high investment in research and development, technical innovation to build core competitiveness. (Daily Economic News)